Anokion SA, a Swiss biotechnology company, has secured $40 million in funding. The investors included Versant Ventures, Novartis Venture Fund, Novo Ventures and Celgene. Also, Anokon has acquired Kanyos Bio Inc. No financial terms were disclosed.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.